Merck & Co., Inc., a pharmaceutical giant based in New Jersey, and its wholly-owned subsidiary MSD Netherlands Capital B.V., headquartered in the Netherlands, have registered a series of debt securities with the U.S. Securities and Exchange Commission (SEC). The securities include 3.250% Notes due 2032, 3.500% Notes due 2037, 3.700% Notes due 2044, and 3.750% Notes due 2054, all to be listed on the New York Stock Exchange. These debt securities are fully and unconditionally guaranteed by Merck & Co. The registration was completed on May 30, 2024, as part of the company's compliance with the Securities Exchange Act of 1934. The registration references detailed descriptions of the debt securities from the Prospectus dated May 14, 2024, and the Prospectus Supplement dated May 16, 2024. The exhibits filed with the SEC include the Indenture and Officer’s Certificates for each series of notes, confirming the formalization of the securities' terms.

Merck & Co., Inc., a pharmaceutical giant based in New Jersey, and its wholly-owned subsidiary MSD Netherlands Capital B.V., headquartered in the Netherlands, have registered a series of debt securities with the U.S. Securities and Exchange Commission (SEC). The securities include 3.250% Notes due 2032, 3.500% Notes due 2037, 3.700% Notes due 2044, and 3.750% Notes due 2054, all to be listed on the New York Stock Exchange. These debt securities are fully and unconditionally guaranteed by Merck & Co. The registration was completed on May 30, 2024, as part of the company's compliance with the Securities Exchange Act of 1934. The registration references detailed descriptions of the debt securities from the Prospectus dated May 14, 2024, and the Prospectus Supplement dated May 16, 2024. The exhibits filed with the SEC include the Indenture and Officer’s Certificates for each series of notes, confirming the formalization of the securities' terms.